Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twice-weekly teriparatide in hemodialysis patients with osteoporosis
jRCTs011230047Recruiting
- Start
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of teriparatide in osteoporosis, chronic kidney disease-mineral and bone disorder (CKD-MBD) and end-stage kidney disease (ESKD) (2 arms). Primary endpoint: Primary: Percent change in lumbar spine BMD at week 48. Started Dec 2023; status: recruiting.
02
Drugs
teriparatide
03
Conditions
osteoporosischronic kidney disease-mineral and bone disorder (CKD-MBD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCTs011230047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011230047.